Article Text

other Versions

PDF
Randomised controlled trial
Nateglinide does not reduce the incidence of diabetes or cardiovascular outcomes in people with impaired glucose tolerance and cardiovascular disease or risk factors
  1. Giuseppe Derosa
  1. Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy
  1. Correspondence to Giuseppe Derosa
    Department of Internal Medicine and Therapeutics, University of Pavia, Fondazione IRCCS Policlinico S. Matteo, P.le C. Golgi, 2 –27100 Pavia, Italy; giuseppe.derosa{at}unipv.it

Statistics from Altmetric.com

Commentary on:

Context

The aim of the NAVIGATOR study was to determine whether the risk of diabetes and cardiovascular events could be reduced in people with impaired glucose tolerance using nateglinide in addition to a lifestyle modification programme.

Methods

Nine thousand three hundred and six adults with impaired glucose tolerance and either cardiovascular disease or cardiovascular risk factors were enrolled in this study and randomly assigned, with the use of an interactive voice-response telephone system, to nateglinide at a dose of 60 mg three times daily or placebo in addition to participation in a lifestyle modification programme. Both the participants and the investigators were unaware of the treatment assignments. Participants returned …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.